COMPASS Pathways (CMPS) Set to Announce Earnings on Thursday

COMPASS Pathways (NASDAQ:CMPS) is set to post its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect COMPASS Pathways to post earnings of ($0.60) per share for the quarter.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.03). During the same period last year, the company earned ($0.62) EPS. On average, analysts expect COMPASS Pathways to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

COMPASS Pathways Stock Down 0.2 %

Shares of NASDAQ CMPS opened at $6.43 on Friday. The stock has a market cap of $439.69 million, a P/E ratio of -2.71 and a beta of 2.26. The firm has a 50 day moving average price of $6.76 and a 200 day moving average price of $7.20. The company has a debt-to-equity ratio of 0.13, a quick ratio of 12.03 and a current ratio of 12.03. COMPASS Pathways has a 52-week low of $5.01 and a 52-week high of $12.75.

Insider Activity

In other news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the transaction, the insider now owns 6,905,774 shares in the company, valued at $41,779,932.70. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 4.25% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on CMPS. HC Wainwright restated a “buy” rating and set a $120.00 price objective on shares of COMPASS Pathways in a report on Friday, August 23rd. Royal Bank of Canada restated an “outperform” rating and set a $23.00 price objective on shares of COMPASS Pathways in a report on Tuesday, September 10th. Canaccord Genuity Group decreased their price objective on shares of COMPASS Pathways from $50.00 to $48.00 and set a “buy” rating for the company in a report on Friday, August 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a report on Monday, September 9th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, COMPASS Pathways has a consensus rating of “Buy” and an average price target of $47.40.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.